Muhammad Aiyaz SharifProduct Manager

PharmEvo Pvt. Ltd

What is Co-enzyme Q10?Coenzyme Q10, also known as ubiquinone, coenzyme Q, and abbreviated at times to CoQ10 .

This oil-soluble, vitamin-like substance is present in most eukaryotic cells, primarily in the mitochondria.

It is a component of the electron transport chain and participates in aerobic cellular respiration, generating energy in the form of ATP.

Ninety-five percent of the human body’s energy is generated this way.1,2

1.Ernster, L; Dallner, G (1995). "Biochemical, physiological and medical aspects of ubiquinone function". Biochimica et Biophysica Acta 1271 (1): 195–204.

2.Dutton, PL; Ohnishi, T; Darrouzet, E; Leonard, MA; Sharp, RE; Cibney, BR; Daldal, F; Moser, CC (2000). "4 Coenzyme Q oxidation reduction reactions in mitochondrial electron transport". In Kagan, VE; Quinn, PJ. Coenzyme Q: Molecular mechanisms in health and disease. Boca Raton: CRC Press. pp. 65–82

Who discovered it?CoQ10 was first discovered by Professor Fredrick L. Crane and colleagues at the University of Wisconsin–Madison Enzyme Institute in 1957.3,4

In 1958, its chemical structure was reported by Dr. Karl Folkers and coworkers at Merck.

In 1961 Peter Mitchell proposed the electron transport chain (which includes the vital proton motive role of CoQ10) and he received a Nobel Prize for the same in 1978.

3.Crane, F; Hatefi, Y; Lester, R; Widmer, C (1957). "Isolation of a quinone from beef heart mitochondria". Biochimica et Biophysica Acta 25 (1): 220–1

4.Peter H. Langsjoen,"Introduction of Coezyme Q10“

What is the role of NeoQ10What is the role of NeoQ10

How is it synthesized?Starting from acetyl-CoA, a multistep process of mevalonate pathway produces farnesyl-PP (FPP), the precursor for cholesterol and CoQ10.

Causes of CoQ10 decrease Causes of CoQ10 decrease

1. Age Dependent Decrease.

2. Use Of Statin.

Why use along with statin?Why use along with statin?

So reduction in cholesterol

leads to reduction in CoQ10

which results in myalgia and

reduced cardio protection

Statin Use

What to do?Add

PharmacokineticsPharmacokinetics

Absorption:Following ingestion of 100 mg of CoQ, peak plasma levels occur between 5 and 10 hours.

T max is approximately 6.5 hours

PharmacokineticsPharmacokinetics

Distribution:

The plasma half-life of CoQ in different tissues varies between 49-125 hours.

Following absorption from the GI tract, CoQ is taken up by chylomicrons. The major portion of an exogenous dose of CoQ is deposited in the liver and packaged into VLDL lipoprotein.

PharmacodynamicsPharmacodynamics

Metabolism/Excretion:It is assumed that metabolism and excretion of exogenous CoQ is analogous to endogenously produced CoQ. The excretion of CoQ is predominantly via the biliary tract.

PharmacodynamicsPharmacodynamics

Drug interaction:

Warfarin: CoQ may antagonize the effects of warfarin. CoQ is structurally similar to vitamin K.

Chemotherapy: Theoretically, CoQ may decrease the efficacy of chemotherapy due to antioxidant activity.

Dosage and IndicationDosage and Indication

• Statin Induced Myalgia.• Age dependent depletion of CO-Q10.• In Patients with major cardiovascular events.• Chronic Fatigue syndrome

Dosage:Dosage:• One capsule twice daily.

Indication:Indication:

Clinical Studies

Am

J Cl

in N

utr

2013

;97:

233–

4

Thank YouThank You

Muhammad Aiyaz SharifMuhammad Aiyaz SharifCell Number: 0333-2292231Cell Number: 0333-2292231

ConclusionConclusion

These patients, steadily worsening and expected to die within 2 years under conventional therapy, generally showed an extraordinary clinical improvement, indicating that CoQ10 therapy might extend the lives of such patients. This improvement could be due to correction of a myocardial deficiency of CoQ10 and to enhanced synthesis of CoQ10-requiring enzymes.

Response of patients in classes III and IV of cardiomyopathy totherapy in a blind and crossover trial with coenzyme Q10

Proc. Nati. Acad. Sci. USAVol. 82, pp. 4240-4244, June 1985

Medical Sciences

A double-blind and double-crossover trial has been conducted by administering CoQ10 and a matching placebo orally to two groups of patients having class I or IV cardiomyopathy (classification according to criteria of the New York Heart Association).

Group A received CoQ10 and then placebo; group B received placebo and then CoQ10. Blood levels of CoQ1o and cardiac function were determined at 0 and 4 weeks (control stabilization period) and at 16 and 28 weeks (after the 12-week CoQ/placebo-treatment periods).

ResultsResults

• For group A, significant increases in CoQ10 blood levels and cardiac function (SV and EF) occurred during CoQ10 treatment and then decreased during crossover to placebo.

• For group B, there was no change in CoQ10 blood levels and cardiac function (SV and EF) during placebo treatment, but increases in both parameters occurred in crossover to CoQ10